RT Journal Article SR Electronic T1 Tourette’s syndrome and its borderland JF Practical Neurology JO Pract Neurol FD BMJ Publishing Group Ltd SP practneurol-2017-001755 DO 10.1136/practneurol-2017-001755 A1 Jeremy S Stern YR 2018 UL http://pn.bmj.com/content/early/2018/04/10/practneurol-2017-001755.abstract AB The Gilles de la Tourette syndrome (or Tourette’s syndrome) has a prevalence of 1% of children with a wide range of severity and associated comorbidities. The last 20 years have seen advances in the understanding of the syndrome’s complex genetics and underlying neurobiology. Investigation with imaging and neurophysiology techniques indicate it is a neurodevelopmental condition with dysfunction of basal ganglia–cortical interactions, which are now also being studied in animal models. There is also increasing evidence for treatments although it often remains difficult to manage. First-line options include neuroleptics, other drugs and specialised behavioural treatments. Deep brain stimulation is an evolving field, not yet fully established. This review focuses on the phenomenology of tics, how to assess and manage the syndrome, and uses examples of atypical cases to explore the characteristics and limits of its clinical spectrum.